DK1315694T3 - Inhibitorer af alpha-4-medieret celleadhæsion - Google Patents

Inhibitorer af alpha-4-medieret celleadhæsion

Info

Publication number
DK1315694T3
DK1315694T3 DK01966246T DK01966246T DK1315694T3 DK 1315694 T3 DK1315694 T3 DK 1315694T3 DK 01966246 T DK01966246 T DK 01966246T DK 01966246 T DK01966246 T DK 01966246T DK 1315694 T3 DK1315694 T3 DK 1315694T3
Authority
DK
Denmark
Prior art keywords
inhibitors
alpha
cell adhesion
mediated cell
mediated
Prior art date
Application number
DK01966246T
Other languages
English (en)
Inventor
Takayuki Kawaguchi
Toshiyuki Kume
Sumihiro Nomura
Mikiko Tsukimoto
Ila Sircar
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Application granted granted Critical
Publication of DK1315694T3 publication Critical patent/DK1315694T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
DK01966246T 2000-08-31 2001-08-27 Inhibitorer af alpha-4-medieret celleadhæsion DK1315694T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22912800P 2000-08-31 2000-08-31
PCT/US2001/026594 WO2002018320A2 (en) 2000-08-31 2001-08-27 INHIBITORS OF α4 MEDIATED CELL ADHESION

Publications (1)

Publication Number Publication Date
DK1315694T3 true DK1315694T3 (da) 2005-08-08

Family

ID=22859926

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01966246T DK1315694T3 (da) 2000-08-31 2001-08-27 Inhibitorer af alpha-4-medieret celleadhæsion

Country Status (28)

Country Link
US (6) US7026501B2 (da)
EP (1) EP1315694B1 (da)
JP (1) JP3899022B2 (da)
KR (1) KR100528049B1 (da)
CN (1) CN1229334C (da)
AR (1) AR034556A1 (da)
AT (1) ATE292615T1 (da)
AU (2) AU8677801A (da)
BR (1) BR0113629A (da)
CA (1) CA2418054C (da)
CZ (1) CZ303460B6 (da)
DE (1) DE60109943T2 (da)
DK (1) DK1315694T3 (da)
ES (1) ES2240509T3 (da)
HK (1) HK1052684B (da)
HU (1) HUP0302693A3 (da)
IL (2) IL154305A0 (da)
MX (1) MXPA03001837A (da)
MY (1) MY129000A (da)
NO (1) NO327861B1 (da)
NZ (1) NZ524043A (da)
PL (1) PL206656B1 (da)
PT (1) PT1315694E (da)
RU (1) RU2250895C2 (da)
SI (1) SI1315694T1 (da)
TW (1) TWI224587B (da)
WO (1) WO2002018320A2 (da)
ZA (1) ZA200301039B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3440469B2 (ja) 2000-08-18 2003-08-25 味の素株式会社 新規フェニルアラニン誘導体
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
CA2443802C (en) 2001-04-27 2010-04-13 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
EP1555265B1 (en) 2002-10-22 2009-03-25 Eisai R&D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7345049B2 (en) * 2003-12-22 2008-03-18 Ajinomoto Co., Inc. Phenylalanine derivatives
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
AU2005320217B2 (en) 2004-12-20 2011-11-10 Eisai R & D Management Co., Ltd. Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine
US7410971B2 (en) 2004-12-24 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
AR054129A1 (es) 2005-06-09 2007-06-06 Uc S A Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
EP2091916A2 (en) * 2005-11-23 2009-08-26 AstraZeneca AB L-phenylalanine derivatives and their use as integrin antagonists
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
EP2386547B1 (en) * 2005-12-29 2018-06-20 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
US20090203663A1 (en) * 2006-02-09 2009-08-13 Astrazeneca Ab Chemical compounds
JP2009528359A (ja) 2006-02-28 2009-08-06 エラン ファーマシューティカルズ，インコーポレイテッド ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2697368C (en) * 2007-08-24 2016-06-21 Lexicon Pharmaceutical Inc. Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
CA2721670C (en) 2008-04-15 2013-09-10 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compound
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
MX2012004707A (es) * 2009-10-21 2012-06-08 Glaxo Group Ltd Proceso para la preparacion de un derivado de fenilalanina.
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
HUE060312T2 (hu) 2010-01-11 2023-02-28 Biogen Ma Inc A JC vírus antitestek vizsgálata
WO2013126595A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye And Ear Infirmary Methods for treating corneal and conjunctival inflammation and inflammatory disorders
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CN114222730A (zh) 2019-08-14 2022-03-22 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
CA2173875A1 (en) 1993-11-01 1995-05-11 Hideyuki Saika Endothelin receptor antagonists
WO1995026360A1 (en) 1994-03-28 1995-10-05 Japat Ltd. Antagonists of endothelin receptors
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
WO1998053817A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
WO1998054207A1 (en) 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
AU8163398A (en) 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
DE69834642T2 (de) 1997-07-31 2007-05-03 Elan Pharmaceuticals, Inc., South San Francisco Verbindungen mit einer 4-amino-phenylalaningruppe, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
HUP0002495A3 (en) 1997-07-31 2001-01-29 American Home Prod Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
ZA986834B (en) 1997-07-31 2000-05-02 Athena Neurosciences Inc Compounds which inhibit leukocyte adhesion mediated by VLA-4.
BR9812114A (pt) 1997-07-31 2000-07-18 Elan Pharm Inc Compostos do tipo fenilalanina substituìda que inibem a adesão de leucócito mediada por vla-4
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
CN1265675A (zh) 1997-07-31 2000-09-06 伊兰药品公司 抑制由vla－4介导的白细胞粘着的苄基化合物
WO1999006433A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
KR20010022405A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개된 백혈구 유착을 억제하는설포닐화된 디펩타이드 화합물
NZ502813A (en) 1997-08-22 2002-10-25 F N-aroylphenylalanine derivatives as inhibitors of the interaction between a4 containing integrins and VCAM-1
DE69821950T2 (de) 1997-08-22 2004-12-16 F. Hoffmann-La Roche Ag N-aroylphenylalaninderivate
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
CA2309338A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
DE69824037T2 (de) 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE69919334T2 (de) 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
AU8059598A (en) 1998-06-11 1999-12-30 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
DK1144365T3 (da) 1998-12-22 2004-06-28 Upjohn Co Inhibitorer af alfa4beta1-medieret celleadhæsion
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
JP2003509488A (ja) 1999-09-24 2003-03-11 ジェネンテック・インコーポレーテッド チロシン誘導体
AU2001284649A1 (en) 2000-08-31 2002-03-13 Eli Lilly And Company Acetylenic sulfonamide derivatives

Also Published As

Publication number Publication date
PL206656B1 (pl) 2010-09-30
CZ303460B6 (cs) 2012-09-26
US7456217B2 (en) 2008-11-25
AR034556A1 (es) 2004-03-03
KR100528049B1 (ko) 2005-11-15
US20100113820A1 (en) 2010-05-06
DE60109943D1 (de) 2005-05-12
ES2240509T3 (es) 2005-10-16
AU2001286778B2 (en) 2005-02-10
RU2250895C2 (ru) 2005-04-27
DE60109943T2 (de) 2006-02-09
IL154305A0 (en) 2003-09-17
ATE292615T1 (de) 2005-04-15
JP2004507519A (ja) 2004-03-11
CN1229334C (zh) 2005-11-30
CA2418054C (en) 2008-08-05
HK1052684A1 (en) 2003-09-26
EP1315694A2 (en) 2003-06-04
CZ2003487A3 (cs) 2003-06-18
NO20030885L (no) 2003-02-25
HUP0302693A2 (hu) 2003-12-29
US20110077299A1 (en) 2011-03-31
BR0113629A (pt) 2003-07-22
US20090111879A1 (en) 2009-04-30
NZ524043A (en) 2004-08-27
CA2418054A1 (en) 2002-03-07
IL154305A (en) 2010-11-30
HUP0302693A3 (en) 2005-05-30
MXPA03001837A (es) 2003-10-15
US7872151B2 (en) 2011-01-18
KR20030059099A (ko) 2003-07-07
EP1315694B1 (en) 2005-04-06
SI1315694T1 (en) 2005-10-31
PL365668A1 (en) 2005-01-10
HK1052684B (zh) 2005-07-22
MY129000A (en) 2007-03-30
US7026501B2 (en) 2006-04-11
PT1315694E (pt) 2005-07-29
CN1449377A (zh) 2003-10-15
AU8677801A (en) 2002-03-13
NO20030885D0 (no) 2003-02-25
TWI224587B (en) 2004-12-01
JP3899022B2 (ja) 2007-03-28
ZA200301039B (en) 2004-02-09
US8501809B2 (en) 2013-08-06
NO327861B1 (no) 2009-10-05
WO2002018320A2 (en) 2002-03-07
US20030176498A1 (en) 2003-09-18
US20130289109A1 (en) 2013-10-31
US20050282900A1 (en) 2005-12-22
WO2002018320A3 (en) 2002-06-06
US7671090B2 (en) 2010-03-02

Similar Documents

Publication Publication Date Title
DK1315694T3 (da) Inhibitorer af alpha-4-medieret celleadhæsion
DK1049662T3 (da) Inhibitorer af alpha4-medieret celleadhæsion
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
DK1064298T3 (da) Inhibitorer af caspaser
IS6289A (is) thríhringja hindrar af poly (ADP-ribosa) polymerösum
DK1077943T3 (da) Heterocykliske inhibitorer af p38
EE200300088A (et) Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena
DK1341779T3 (da) Heterocyklisk sulfonamid-inhibitorer af beta-amyloidproduktion
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DK1438306T3 (da) Derivater af UK-2A
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
DK1686113T3 (da) Inhibitorer af aspartylprotease
DE60008527D1 (de) Zellproliferation inhibitoren
DK1362050T3 (da) Pyrimidinderivater til inhibition af celleproliferation
PT1181017E (pt) Inibidores de metaloproteases
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1470732T3 (da) Fremskaffelse af lokaliseringsinformation
DE60131992D1 (de) Pfropfcopolymere enthaltende klebstoffe
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DK1144425T3 (da) Derivater af monosaccharider som celleadhæsionsinhibitorer
IS6215A (is) Að mestu leyti kristallað form af melagatrani
ATE411995T1 (de) Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion
IS6620A (is) Nýr fjölgervingur V af tórasemíði
DE50103366D1 (de) Polare Acrylathaftklebemassen
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren